LuciErlo 150mg, Erlotinib Tablets

Erlotinib, the active ingredient of LuciErlo 150mg, a targeted anti-cancer drug, is mainly used to treat pancreatic and non-small cell lung cancer (NSCLC). It falls under the class of drugs known as tyrosine kinase inhibitors (TKIs) and specifically targets the epidermal growth factor receptor (EGFR). Manufactured as an oral tablet, LuciErlo offers a more tailored approach to cancer therapy by blocking the growth signals of cancer cells.

What is LuciErlo 150mg (Erlotinib)?

LuciErlo 150mg is a prescription drug designed to inhibit the activity of EGFR tyrosine kinase, a protein found in various cancer cells that promotes tumor growth and proliferation. The active component, erlotinib, works particularly well in people who have particular EGFR mutations, which are frequently observed in patients with lung cancer. It is marketed in India and other regions as a cost-effective alternative to brand-name Erlotinib formulations.

How It Works / Mechanism of Action

Erlotinib functions by selectively inhibiting the intracellular phosphorylation of tyrosine kinase associated with the EGFR. Many malignancies, especially non-small cell lung cancer, have mutations or overexpression of this receptor. By blocking EGFR activity:

• It inhibits signal transduction pathways that lead to cell proliferation.
• Promotes cell cycle arrest and apoptosis (programmed cell death).
• Limits tumor angiogenesis (formation of new blood vessels feeding the tumor).
• This mechanism is especially beneficial for patients with activating EGFR mutations, making the drug more effective in such genetically defined cancers.

How to Use / Indications

LuciErlo 150mg is indicated for the treatment of:

• Non-Small Cell Lung Cancer (NSCLC) – Especially in patients with EGFR mutations and who have failed previous chemotherapy.
• Pancreatic Cancer: For individuals with locally advanced, incurable, or metastatic pancreatic cancer, in conjunction with gemcitabine.
• Off-label uses – In certain cases of head and neck cancers and other solid tumors with EGFR mutations (doctor discretion).
• Patients should be tested for EGFR mutations before starting therapy to ensure the best possible response.

How to Take / Dosage

Standard Dose:

• NSCLC: 150mg once daily.
• For Pancreatic Cancer (with gemcitabine): 100mg once daily.

Administration Instructions:

• Take LuciErlo at least one hour before or two hours after eating, as food increases drug absorption and can enhance side effects.
• Swallow the tablet whole with water, preferably at the same time each day.

Note: Dose adjustments may be required in patients experiencing severe side effects or those with liver/kidney impairment.

Other Dosages

LuciErlo is also available in other strengths such as 25mg, 100mg, and generic formulations to allow for flexible dose adjustment:

• 100mg/day for patients with pancreatic cancer.
• Reduced doses in patients with adverse effects like severe diarrhea, rash, or liver toxicity.

Side Effects

Common side effects include:

• Skin Rash – Most frequent and often indicates effectiveness.
• Diarrhea
• Fatigue
• Anorexia and weight loss
• Nausea and vomiting
• Mouth sores
• Dry skin and itching
• Cough or shortness of breath

Serious side effects (less common):

• Interstitial lung disease (ILD)
• Hepatotoxicity
• Gastrointestinal perforation
• Eye irritation or conjunctivitis
• Report any unusual or severe symptoms to a healthcare provider immediately.

Storage

• Store LuciErlo tablets at room temperature (15–30°C).
• Keep away from moisture and direct sunlight.
• Store in the original container to protect from light.
• Keep out of reach of children and pets.

Benefits

• Targeted therapy: Particularly stops the growth of cancer cells in tumors that are EGFR positive.
• enhanced progression-free survival in individuals with EGFR mutations who had non-small cell lung cancer.
• Convenient oral formulation, no need for hospital-based IV administration.
• Well-tolerated compared to traditional chemotherapy.
• Delayed disease progression when used in advanced cancers.

Prescription

LuciErlo is a prescription-only medication. It must be:

• Prescribed by an oncologist after diagnostic confirmation of EGFR mutation.
• Administered under strict medical supervision.
• Doses and treatment duration are individualized based on patient response and tolerance.
• Do not self-medicate or discontinue without consulting your doctor.
• Interaction

LuciErlo may interact with:

• CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin) – Affects drug metabolism.
• Proton Pump Inhibitors (PPIs) and antacids – Reduce absorption of Erlotinib.
• Warfarin and anticoagulants – May increase bleeding risk.
• Smoking – Reduces the efficacy of Erlotinib by enhancing its clearance.
• Chemotherapy agents – Can increase toxicity when used without proper planning.

Inform your doctor of all medications, supplements, and herbal products you’re using.

FAQs

How long does one need to take LuciErlo?

Duration varies. Some patients continue for months or years depending on disease progression and tolerance.

Can I smoke while on Erlotinib?

No, smoking reduces the effectiveness of Erlotinib.

What happens if I miss a dose?

Skip it if close to the next dose. Do not double up.

Conclusion

LuciErlo 150mg (Erlotinib) is a vital component of targeted cancer therapy, especially in EGFR mutation-positive non-small cell lung cancer and pancreatic cancer. It offers a patient-friendly oral alternative to chemotherapy with fewer systemic side effects. However, close observation is required for pulmonary problems, diarrhea, and rash. Proper mutation testing, adherence to dosage instructions, and regular follow-ups with the oncologist are key to maximizing the benefits of this therapy.